{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:37:35Z","timestamp":1792193855732,"version":"4.4.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,7,14]]},"DOI":"10.1001\/jama.2020.11301","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T15:32:10Z","timestamp":1592580730000},"page":"168","source":"Crossref","is-referenced-by-count":319,"title":["Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality"],"prefix":"10.1001","volume":"324","author":[{"given":"Emil L.","family":"Fosb\u00f8l","sequence":"first","affiliation":[{"name":"The Heart Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad H.","family":"Butt","sequence":"additional","affiliation":[{"name":"The Heart Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauge","family":"\u00d8stergaard","sequence":"additional","affiliation":[{"name":"The Heart Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Andersson","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Selmer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Kragholm","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Phelps","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Epidemiology and Research, The Danish Heart Foundation, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar H.","family":"Gislason","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark"},{"name":"Department of Cardiovascular Epidemiology and Research, The Danish Heart Foundation, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Gerds","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Epidemiology and Research, The Danish Heart Foundation, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Department of Cardiology, Hiller\u00f8d Hospital, Hiller\u00f8d, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"The Heart Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"joi200074r1","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa041","article-title":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.","volume":"27","author":"Diaz","year":"2020","journal-title":"J Travel Med"},{"issue":"5","key":"joi200074r2","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/HJH.0000000000002450","article-title":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?","volume":"38","author":"Esler","year":"2020","journal-title":"J Hypertens"},{"issue":"4","key":"joi200074r3","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"18","key":"joi200074r4","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China.","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"joi200074r5","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016509","article-title":"Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect?","volume":"9","author":"Sommerstein","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"joi200074r6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"6965","key":"joi200074r7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"issue":"17","key":"joi200074r10","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19.","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"joi200074r11","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China.","author":"Li","journal-title":"JAMA Cardiol"},{"key":"joi200074r12","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of COVID-19.","author":"Mancia","journal-title":"N Engl J Med"},{"key":"joi200074r13","article-title":"Association of use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with testing positive for coronavirus disease 2019 (COVID-19).","author":"Mehta","journal-title":"JAMA Cardiol"},{"key":"joi200074r14","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19.","author":"Reynolds","journal-title":"N Engl J Med"},{"key":"joi200074r15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/CLEP","article-title":"The Danish health care system and epidemiological research: from health care contacts to database records.","volume":"11","author":"Schmidt","year":"2019","journal-title":"Clin Epidemiol"},{"issue":"11","key":"joi200074r16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012832","article-title":"Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study.","volume":"6","author":"Sundb\u00f8ll","year":"2016","journal-title":"BMJ Open"},{"key":"joi200074r17","doi-asserted-by":"publisher","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study.","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"joi200074r18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/bimj.v62.3","article-title":"On the estimation of average treatment effects with right-censored time to event outcome and competing risks.","volume":"62","author":"Ozenne","year":"2020","journal-title":"Biom J"},{"issue":"11","key":"joi200074r20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1042\/CS20120162","article-title":"Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.","volume":"123","author":"Burchill","year":"2012","journal-title":"Clin Sci (Lond)"},{"issue":"20","key":"joi200074r21","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"issue":"2","key":"joi200074r22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/(ISSN)1096-9896","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus: a first step in understanding SARS pathogenesis.","volume":"203","author":"Hamming","year":"2004","journal-title":"J Pathol"},{"issue":"1","key":"joi200074r23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.mce.2011.07.041","article-title":"Modulation of AT-1R\/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice.","volume":"348","author":"Lakshmanan","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"joi200074r24","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1161\/01.HYP.0000237862.94083.45","article-title":"Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat.","volume":"48","author":"Ocaranza","year":"2006","journal-title":"Hypertension"},{"issue":"2","key":"joi200074r25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.mce.2011.12.010","article-title":"Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor.","volume":"351","author":"Sukumaran","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"joi200074r26","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3109\/10715762.2012.684878","article-title":"Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 mas receptor.","volume":"46","author":"Sukumaran","year":"2012","journal-title":"Free Radic Res"},{"issue":"1-3","key":"joi200074r27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.regpep.2010.09.005","article-title":"Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression.","volume":"166","author":"Zhong","year":"2011","journal-title":"Regul Pept"},{"issue":"23","key":"joi200074r28","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"issue":"23","key":"joi200074r29","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).","volume":"316","author":"Group","year":"1987","journal-title":"N Engl J Med"},{"issue":"25","key":"joi200074r30","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction.","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N Engl J Med"},{"issue":"10166","key":"joi200074r31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"joi200074r32","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/0735-1097(93)90578-O","article-title":"Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril.","volume":"22","author":"Pflugfelder","year":"1993","journal-title":"J Am Coll Cardiol"},{"issue":"10229","key":"joi200074r36","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"joi200074r37","article-title":"COVID-19 and renin angiotensin blockers: current evidence and recommendations.","author":"Messerli","journal-title":"Circulation"},{"key":"joi200074r19","volume-title":"Handbook of Survival Analysis","author":"Borgan","year":"2013"},{"key":"joi200074r8","doi-asserted-by":"crossref","unstructured":"Bozkurt? B, Kovacs? R, Harrington? R. HFSA\/ACC\/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Published 2020. Accessed May 2, 2020. https:\/\/professional.heart.org\/professional\/ScienceNews\/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp","DOI":"10.1016\/j.cardfail.2020.04.013"},{"key":"joi200074r9","unstructured":"European Society of Cardiology. Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers. Published March 13, 2020. Accessed June 12, 2020. https:\/\/www.escardio.org\/Councils\/Council-on-Hypertension-(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang"},{"key":"joi200074r33","unstructured":"ClinicalTrials.gov. Coronavirus (COVID-19) ACEi\/ARB investigation (CORONACION). ClinicalTrials.gov identifier: NCT04330300. Accessed June 10, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04330300"},{"key":"joi200074r34","unstructured":"ClinicalTrials.gov. ACE inhibitors or ARBs discontinuation in context of SARS-CoV-2 pandemic (ACORES-2). ClinicalTrials.gov identifier: NCT04329195. Accessed June 10, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04329195"},{"key":"joi200074r35","unstructured":"ClinicalTrials.gov. Losartan for Patients With COVID-19 Not Requiring Hospitalization. ClinicalTrials.gov identifier: NCT04311177. Accessed June 10, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04311177"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2767669\/jama_fosbl_2020_oi_200074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T15:26:41Z","timestamp":1594740401000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2767669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,7,14]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.11301","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,14]]}}}